| Title | Drug interactions with new and investigational antiretrovirals. | | Author(s) | Brown KC, Paul S, Kashuba AD | | Institution | School of Pharmacy, Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. | | Source | Clin Pharmacokinet 2009; 48(4):211-41. | | Abstract | More than 20 individual and fixed-dose combinations of antiretrovirals are approved for the treatment of human immunodeficiency virus (HIV) infection. However, owing to the ongoing limitations of drug resistance and adverse effects, new treatment options are still required. A number of promising new agents in existing or new drug classes are in development or have recently been approved by the US FDA. Since these agents will be used in combination with other new and existing antiretrovirals, understanding the potential for drug interactions between these compounds is critical to their appropriate use. This article summarizes the drug interaction potential of new and investigational protease inhibitors (darunavir), non-nucleoside reverse transcriptase inhibitors (etravirine and rilpivirine), chemokine receptor antagonists (maraviroc, vicriviroc and INCB 9471), integrase inhibitors (raltegravir and elvitegravir) and maturation inhibitors (bevirimat). | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19492868 |
|
